Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 EFZO-CONNE ...
Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine ...
The Foundation for Sarcoidosis Research (FSR) has been named a 2025 RareVoice Awards recipient by EveryLife Foundation for Rare Diseases, earning national recognition for Federal Advocacy by a Patient ...
Please provide your email address to receive an email when new articles are posted on . Approximately 40,000 people in the United States have skin sarcoidosis and there is no FDA-approved treatment.
CHICAGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) has awarded four grants in the amount of $100,000 each to Dr. Christen Vagts from the University of Illinois at ...
The study did not meet the primary endpoint of change from baseline in mean daily oral corticosteroid dose at week 48. Topline data were announced from a phase 3 trial evaluating efzofitimod in ...
aTyr Pharma experienced a catastrophic trading session Monday as shares plummeted 83% following the announcement that its pivotal Phase 3 clinical trial failed to meet its primary endpoint. The ...
NORTH PLAINFIELD, N.J. (WPVI) -- The immune system helps protect us against disease, but sometimes, it becomes the source of trouble. That's the case with sarcoidosis. "I apparently had it since I was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results